Background The European Cystic Fibrosis (CF) Society Patient Registry collects demographic and clinical data from consenting people with CF in Europe. The Registry’s database contains data of over 49,000 patients from 38 countries. High quality data is essential for use in annual reports, epidemiological research and postauthorisation studies. Methods A validation programme was introduced to quantify consistency and accuracy of data-input at source level, and verify that the informed consent – required to include data in the Registry – has been obtained in accordance with local and European legislation. Accuracy is defined as the proportion of values in the software that match the medical record, and consistency as definitions used by the centre that match those defined and required by the Registry. The data fields to verify: demographic, diagnostic, transplantation, anthropometric and lung function measurement, bacterial infections, medications and complications. The number of countries to validate: 20% of the total countries per year, max. 5 countries/year. In the selected country ≥10% of the centres are to be visited and 15-20% of patients’ data validated. The visits are limited to centres with ≥50 patients. Results In a one day visit the aim of the programme was explained to the centre, the data included in the Registry were compared with the medical records, the outcomes and recommendations discussed, and a final report provided to the centre. Challenges proved to be: informed consent (re-consent at adult age or when the patient moved centre), mutation information (genetic laboratory report missing), different interpretations of the definitions. The outcomes of the validation visits are presented in Figure 1. Conclusions Validation visits are essential to optimise data quality at source, ensure centres are aware of the importance of correct informed consent and encourage dialogue to gain insight in how procedures, software, support and training can be improved.

The European Cystic Fibrosis Society Patient Registry’s Data Quality programme / J. Van Rens, A. Fox, M. Krasnyk, A. Orenti, A. Zolin, A. Jung, L. Naehrlich. ((Intervento presentato al 10. convegno European Conference on Rare Diseases and Orphan Products tenutosi a online nel 2020.

The European Cystic Fibrosis Society Patient Registry’s Data Quality programme

A. Orenti;A. Zolin;
2020

Abstract

Background The European Cystic Fibrosis (CF) Society Patient Registry collects demographic and clinical data from consenting people with CF in Europe. The Registry’s database contains data of over 49,000 patients from 38 countries. High quality data is essential for use in annual reports, epidemiological research and postauthorisation studies. Methods A validation programme was introduced to quantify consistency and accuracy of data-input at source level, and verify that the informed consent – required to include data in the Registry – has been obtained in accordance with local and European legislation. Accuracy is defined as the proportion of values in the software that match the medical record, and consistency as definitions used by the centre that match those defined and required by the Registry. The data fields to verify: demographic, diagnostic, transplantation, anthropometric and lung function measurement, bacterial infections, medications and complications. The number of countries to validate: 20% of the total countries per year, max. 5 countries/year. In the selected country ≥10% of the centres are to be visited and 15-20% of patients’ data validated. The visits are limited to centres with ≥50 patients. Results In a one day visit the aim of the programme was explained to the centre, the data included in the Registry were compared with the medical records, the outcomes and recommendations discussed, and a final report provided to the centre. Challenges proved to be: informed consent (re-consent at adult age or when the patient moved centre), mutation information (genetic laboratory report missing), different interpretations of the definitions. The outcomes of the validation visits are presented in Figure 1. Conclusions Validation visits are essential to optimise data quality at source, ensure centres are aware of the importance of correct informed consent and encourage dialogue to gain insight in how procedures, software, support and training can be improved.
mag-2020
Settore MED/01 - Statistica Medica
The European Cystic Fibrosis Society Patient Registry’s Data Quality programme / J. Van Rens, A. Fox, M. Krasnyk, A. Orenti, A. Zolin, A. Jung, L. Naehrlich. ((Intervento presentato al 10. convegno European Conference on Rare Diseases and Orphan Products tenutosi a online nel 2020.
Conference Object
File in questo prodotto:
File Dimensione Formato  
Abstract_ECRD2020.pdf

accesso aperto

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 508.04 kB
Formato Adobe PDF
508.04 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/745678
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact